Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors

Title:Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors

Volume: 12 Issue: 5

Author(s): Giampiero Giovacchini, Guillaume Nicolas and Flavio Forrer

Affiliation:

Keywords: Neuroendocrine tumors, Peptide receptor radionuclide therapy, Somatostatin receptors, Epidemiology, Diagnosis, Radiopharmaceuticals, Radionuclides, Plane waves, octreotide, spleen

Abstract: Neuroendocrine tumors (NETs) are rare tumors with variable malignant behavior. The majority of NETs express increased levels of somatostatin (SST) receptors, particularly SST2 receptors. Radiolabeled peptides specific for the SST2 receptors may be used for diagnosis of NETs and for peptide receptor radionuclide therapy (PRRT). [111In-DTPA0]-octreotide has been the first peptide used for PRRT. This radiolabeled peptide, emitting Auger electrons, often induced symptomatic relief, but objective morphological responses were rarely documented. After the introduction of the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) other peptides, primarily [DOTA(0),Tyr(3)]octreotate (DOTATATE) and [DOTA(0),Tyr(3)]octreotide (DOTATOC) were labeled with 90Y or 177Lu and used for therapy applications. The rate of objective response obtained with these radiolabeled peptides ranges between 6% and 46%, owing to differences in inclusion criteria adopted in different studies, length and type of therapy, and criteria of evaluation of the response. The present data in the literature do not allow defining the most suitable peptide and radionuclide for the treatment of NETs. Instead emerging evidence indicates that a combination of nuclides with different physical characteristics might be more effective than the use of a single nuclide. Kidney and bone marrow toxicity are the limiting factors for PRRT. Mild toxicity is often encountered while severe toxicity is rarer. Toxicity could be reduced and therapeutic efficacy enhanced by patient-specific dosimetry. Future directions include different issues of PRRT, such as defining the most suitable treatment scheme, evaluation of new peptides with different affinity profiles to other SST receptor subtypes, and reduction of toxicity.

Cite this article as:

Giovacchini Giampiero, Nicolas Guillaume and Forrer Flavio, Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (5) . https://dx.doi.org/10.2174/187152012800617803